**Supplementary Table 2.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***KRAS* mutation** | ***PIK3CA* tested/ Total** | ***PIK3CA* mutation** | | **Incidence *PIK3CA*** | **Ratio Exon 20/9** |
| **Exon 9** | **Exon 20** |
| p.G12A | 11/14 | 2 | 2 | 36% | 50% |
| p.G12C | 6/11 | 1 | 1 | 33% | 50% |
| p.G12D | 23/31 | 4 | 1 | 22% | 20% |
| p.G12V | 15/23 | 1 | 1 | 13% | 50% |
| p.G13D | 10/13 | 1 | 0 | 10% | 0% |

\*Only *KRAS* mutations observed in more than 10 patients were included